Home-SINOPEP-诺泰生物

  • download.jpg download.jpg
    Driving Innovations in Pharmaceuticals
  • download.jpg download.jpg
    Driving Innovations in Pharmaceuticals

Why SINOPEP?

An Unique TIDEs Platform with Cutting Edge Technologies

As one of the industry leaders in therapeutic peptides, Sinopep is the exclusive API supplier for Albuvirtide and Lanreotide 505b2, two of the top five highly demanded peptide products. We are the leading  API provider of Semaglutide, Tirzepatide, and Liraglutide worldwide, accounted for majority of export quantity of these highly demanded peptide APIs currently on the market.  Sinopep not only consistently delivers the best quality peptide APIs, but also provides the most complete documentation meeting the highest global quality and regulatory requirement. Meanwhile, our advanced technologies in both process development and manufacturing enable Sinopep to produce these peptides in an extremely efficient manner with high yield and among the largest batch sizes known to date.  Sinopep also excels in providing efficient, flexible, and high-quality end-to-end CRDMO services encompassing multiple modalities such as peptides, oligonucleotides, small molecules, and related synthetic conjugates etc. It makes Sinopep one of the most trusted worldwide partners in pharmaceutical and healthcare industries.

Core Strengths

未标题-1.jpg
  • a1_icon_01.svg
    Technically Advanced Peptide Solutions

    As the exclusive API supplier of Albuvirtide and Lanreotide 505b2, two of the top five highly demanded peptide APIs, Sinopep is proud of being one of the most trusted partners and technically advanced peptide solution provider for many leading pharmaceuticals and biotech companies.

  • a1_icon_02.svg
    Dominance in the Peptide Landscape

    Accounted for major exports of the three most demanded peptide APIs, we spearheaded the industry by supporting multinational pharmaceutical corporations for their first generic enterprise’s filings for ANDA.

  • Frame.svg
    FDA Approved Facility & Recognition
    • Passed three FDA inspections from 2014 to 2019

    • Semaglutide and Liraglutidle earned coveted FDA  Active Pharmaceutical Ingredient (APl) First Adequate (FA) Letters

  • a1_icon_04.svg
    Innovation Driven Research & Development
    • Innovative LPPS/SPPS hybrid synthesis

    • Five characterization methods to confirm API structure

    • Thorough and comprehensive studies on potential impurities

Products & Services

We are offering high-quality products and solutions to our worldwide partners from preclinical to commercial.

  • CRDMO
  • APIs
  • Intermediates
  • a1_img_05.jpg
    CRDMO
    Sinopep's elite CMC team offers end-to-end support, executing efficiently and seamlessly from conception to commercial launch. With customer specific solutions, industry-leading expertise, and a strong commitment to execution excellence, we ensure development activities are planned and monitored with meticulous guidance and regulatory compliance, in order to accelerating your product's journey to success.
  • Frame 129.png
    APIs
    Complete the development of starting materials and API processes quickly control the cost of materials.
  • Frame 134.png
    Intermediates
    Our individual reactors ranging from 100 L to 10,000 L, allowing us to deliver client's product at any scale and support both development requirements and commercial supply needs.

Optimized Drug Development: Scouting to Commercialization

We seamlessly traverse route scouting and process R&D to full-scale commercialization. As a highly multidisciplinary team, we blend organic synthesis methodologies with state-of-the-art biological transformation, while enhancing API and drug product yield and purity. Our commitment to operation efficiency and cost-efectiveness propels technical innovations and their application in drug development, maximizing economical value to our valued customers as well as patients.

a1_img_09.jpg